SG11201505206WA - T-type calcium channel inhibitors for treatment of cancer - Google Patents
T-type calcium channel inhibitors for treatment of cancerInfo
- Publication number
- SG11201505206WA SG11201505206WA SG11201505206WA SG11201505206WA SG11201505206WA SG 11201505206W A SG11201505206W A SG 11201505206WA SG 11201505206W A SG11201505206W A SG 11201505206WA SG 11201505206W A SG11201505206W A SG 11201505206WA SG 11201505206W A SG11201505206W A SG 11201505206WA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- calcium channel
- type calcium
- channel inhibitors
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Radiology & Medical Imaging (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361751038P | 2013-01-10 | 2013-01-10 | |
PCT/US2014/011098 WO2014110409A2 (en) | 2013-01-10 | 2014-01-10 | T-type calcium channel inhibitors for treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201505206WA true SG11201505206WA (en) | 2015-07-30 |
Family
ID=51167513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201505206WA SG11201505206WA (en) | 2013-01-10 | 2014-01-10 | T-type calcium channel inhibitors for treatment of cancer |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150355163A1 (en) |
EP (1) | EP2943583A4 (en) |
JP (1) | JP2016506248A (en) |
KR (1) | KR20150108853A (en) |
CN (1) | CN105189775A (en) |
AU (1) | AU2014205255A1 (en) |
CA (1) | CA2897005A1 (en) |
HK (1) | HK1216548A1 (en) |
IL (1) | IL239768A0 (en) |
MX (1) | MX2015008982A (en) |
SG (1) | SG11201505206WA (en) |
WO (1) | WO2014110409A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016341429B2 (en) | 2015-10-22 | 2023-09-21 | Cavion, Inc. | Methods for treating Angelman Syndrome and related disorders |
KR102642063B1 (en) | 2017-02-15 | 2024-03-04 | 카비온, 인코포레이티드 | calcium channel inhibitor |
IL270180B (en) | 2017-04-26 | 2022-06-01 | Cavion Inc | Methods for improving memory and cognition and for treating memory and cognitive disorders |
US20200129492A1 (en) * | 2017-07-03 | 2020-04-30 | Menri Group Ltd. | Treatment of cancer with dihydropyridines |
KR102217010B1 (en) * | 2018-01-26 | 2021-02-18 | 재단법인 대구경북첨단의료산업진흥재단 | Pharmaceutical composition for use in preventing or treating cancer containing calcium channel blocker or pharmaceutically acceptable salts thereof as an active ingredient |
IL300798A (en) | 2018-10-03 | 2023-04-01 | Cavion Inc | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
CN110742890A (en) * | 2019-10-24 | 2020-02-04 | 暨南大学 | Application of lomerizine in preparation of anti-colon cancer drug |
CN116139144A (en) * | 2021-11-19 | 2023-05-23 | 双运生物医药科技(苏州)有限公司 | Application of flunarizine targeted ZDHC 5 in preparation of glioma treatment drugs |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2501233A1 (en) * | 2002-10-10 | 2004-04-22 | Merck & Co., Inc. | Assay methods for state-dependent calcium channel agonists/antagonists |
US20080194669A1 (en) * | 2004-08-20 | 2008-08-14 | Gray Lloyd S | T Type Calcium Channel Blockers and the Treatment of Diseases |
EP1968596A4 (en) * | 2005-12-22 | 2010-12-01 | Icagen Inc | Calcium channel antagonists |
-
2014
- 2014-01-10 EP EP14737609.9A patent/EP2943583A4/en not_active Withdrawn
- 2014-01-10 WO PCT/US2014/011098 patent/WO2014110409A2/en active Application Filing
- 2014-01-10 CN CN201480013009.4A patent/CN105189775A/en active Pending
- 2014-01-10 AU AU2014205255A patent/AU2014205255A1/en not_active Abandoned
- 2014-01-10 SG SG11201505206WA patent/SG11201505206WA/en unknown
- 2014-01-10 MX MX2015008982A patent/MX2015008982A/en unknown
- 2014-01-10 JP JP2015552820A patent/JP2016506248A/en active Pending
- 2014-01-10 KR KR1020157021022A patent/KR20150108853A/en not_active Application Discontinuation
- 2014-01-10 CA CA2897005A patent/CA2897005A1/en not_active Abandoned
- 2014-01-10 US US14/760,282 patent/US20150355163A1/en not_active Abandoned
-
2015
- 2015-07-02 IL IL239768A patent/IL239768A0/en unknown
-
2016
- 2016-04-15 HK HK16104344.7A patent/HK1216548A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2014205255A1 (en) | 2015-07-23 |
EP2943583A4 (en) | 2016-08-31 |
US20150355163A1 (en) | 2015-12-10 |
HK1216548A1 (en) | 2016-11-18 |
CA2897005A1 (en) | 2014-07-17 |
KR20150108853A (en) | 2015-09-30 |
EP2943583A2 (en) | 2015-11-18 |
MX2015008982A (en) | 2016-06-14 |
IL239768A0 (en) | 2015-08-31 |
WO2014110409A3 (en) | 2015-10-22 |
JP2016506248A (en) | 2016-03-03 |
CN105189775A (en) | 2015-12-23 |
WO2014110409A2 (en) | 2014-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL241232A0 (en) | Compounds for treatment of cancer | |
EP2968348A4 (en) | Compounds for treatment of cancer | |
HK1217289A1 (en) | Compositions and methods for treatment of cancer using bacteria | |
HK1216548A1 (en) | T-type calcium channel inhibitors for treatment of cancer t- | |
IL285077A (en) | Compounds for treatment of cancer | |
EP2977014A4 (en) | Catheter for treatment of sinusitis | |
HK1213817A1 (en) | Methods of treating cancer | |
HK1219737A1 (en) | Novel compounds for the treatment of cancer | |
HK1223547A1 (en) | Methods for the treatment of cancer | |
HK1219513A1 (en) | Methods of treating cancer | |
EP2986294A4 (en) | Compounds for treatment of pain | |
GB201607581D0 (en) | Treatment of cancer | |
EP2897607A4 (en) | Inhibitors of beta-hydrolase for treatment of cancer | |
PL3082860T3 (en) | Method of treating wounds | |
HK1232118A1 (en) | Treatment of cancer | |
ZA201506396B (en) | Use of sedoheptulose for prevention or treatment of inflammation | |
EP3000465A4 (en) | T-type calcium channel inhibitor | |
EP2986295A4 (en) | Compounds for treatment of pain | |
PL3016948T3 (en) | 2-acylaminothiazoles for the treatment of cancer | |
EP3007712A4 (en) | Treatment of cancer | |
EP3079771A4 (en) | Sgk1 inhibitors for treatment of prostate cancer | |
GB201322347D0 (en) | Treatment of cancer | |
GB201318742D0 (en) | Treatment of cancer | |
AP2015008905A0 (en) | Novel compounds for the treatment of cancer | |
GB201308529D0 (en) | Treatment of cancer |